General
Preferred name
pergolide
Synonyms
PERGOLIDE MESYLATE ()
Pergolide methanesulfonate ()
CPD000058504 ()
LY127809 ()
Pergolide mesylate salt ()
Permax ()
Pergolide (mesylate) ()
NSC-319773 ()
LY-127809 ()
LY 127809 ()
NSC-758442 ()
Celance ()
Pergolide mesilate ()
P&D ID
PD009755
CAS
66104-23-2
66104-22-1
Tags
drug
natural product
biased GPCR ligand
available
Approved by
FDA
First approval
1988
Drug Status
investigational
withdrawn
approved
vet_approved
Drug indication
Parkinson disease
Dopamine Agonist
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Marketed formulations may contain pergolide mesylate (PubChem CID 47812). (GtoPdb)
DESCRIPTION Dopamine receptor agonist; antiparkinsonian (LOPAC library)
DESCRIPTION Pergolide Mesylate is an antiparkinsonian agent which functions as a dopaminergic agonist. (BOC Sciences Bioactive Compounds)
DESCRIPTION Pergolide (Permax, Pergotoliderived) is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with low levels of the neurotransmitter dopamine in the brain. Pergolide has some of the same effects as dopamine in the body. In 2007, pergolide was withdrawn from the U.S. market after several published studies revealed a link between the drug and increased rates of valvular dysfunction. (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
2
Compound Sets
27
AdooQ Bioactive Compound Library
A14179
BiasDB
Pergolide
Bioprocess diversity set
BOC Sciences Bioactive Compounds
pergolide-mesylate-cas-66104-23-2-item-84-74687
pergolide-cas-66104-22-1-item-84-96557
Cayman Chemical Bioactives
26085
ChEMBL Approved Drugs
CHEMBL1275
CHEMBL531
ChEMBL Drugs
CHEMBL1275
CHEMBL531
Drug Repurposing Hub
DrugBank
DB01186
DrugBank Approved Drugs
DB01186
DrugCentral
2105
DrugCentral Approved Drugs
2105
DrugMAP
DM14MAE
DrugMAP Approved Drugs
DM14MAE
EU-OPENSCREEN Bioactive Compound Library
EOS100629
Guide to Pharmacology
48
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL531
MedChem Express Bioactive Compound Library
HY-13720A
Natural product-based probes and drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Pergolide-mesylate
TargetMol Bioactive Compound Library
T2226
Withdrawn 2.0
w169
External IDs
64
Properties
(calculated by RDKit )
Molecular Weight
314.18
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
4.27
TPSA
19.03
Fraction CSP3
0.58
Chiral centers
3.0
Largest ring
6.0
QED
0.91
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
D2/D1
Biological process
rRNA & ncRNA processing
Pathway
Neuroscience
GPCR/G protein
Neuronal Signaling
Target
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C
MOA
Dopamine Receptor agonist
ATC
N04BC02
Toxicity type
cardiovascular
Biosynthetic Origin
Alkaloid
Therapeutic Indication
Alzheimer's Disease
Therapeutic Class
CNS & PNS
Antiparkinson Agents
Source data